Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus for renal function in heart transplant patients
NCT00121784Phase 4Terminated
- Sponsor
- Roche
- Start
- Oct 2005
- Primary completion
- Aug 2006
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 4, randomised, open-label trial of sirolimus in chronic kidney disease (CKD) (2 arms), sponsored by Roche. Primary endpoints: Renal function assessed by calculated Glomerular Filtration Rate at 24 months and Incidence of biopsy-proven acute rejection (BPAR) or HDC, graft loss or lost to follow-up. Started Oct 2005; status: terminated.
02
Drugs
sirolimus
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT00121784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00121784.